Acuta Capital Partners as of Dec. 31, 2021
Portfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 36 positions in its portfolio as reported in the December 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Aadi Bioscience (AADI) | 15.5 | $37M | 1.5M | 24.15 | |
| Apellis Pharmaceuticals (APLS) | 10.6 | $25M | 535k | 47.28 | |
| Vistagen Therapeutics Com New | 9.6 | $23M | 12M | 1.95 | |
| Celldex Therapeutics Com New (CLDX) | 5.5 | $13M | 340k | 38.64 | |
| Gh Research Ordinary Shares (GHRS) | 4.1 | $9.8M | 420k | 23.33 | |
| Relmada Therapeutics (RLMD) | 3.8 | $9.1M | 404k | 22.53 | |
| Bcls Acquisition Corp- Cl A Com Cl A | 3.5 | $8.3M | 843k | 9.80 | |
| Iveric Bio | 3.3 | $7.9M | 470k | 16.72 | |
| Merus N V (MRUS) | 3.1 | $7.5M | 236k | 31.80 | |
| Pyxis Oncology Inc Series B Common Stock (PYXS) | 3.1 | $7.4M | 678k | 10.97 | |
| Xenon Pharmaceuticals (XENE) | 3.0 | $7.0M | 225k | 31.24 | |
| Arrowhead Pharmaceuticals (ARWR) | 2.9 | $7.0M | 106k | 66.30 | |
| Miragen Therapeutics (VRDN) | 2.6 | $6.3M | 318k | 19.77 | |
| Jiya Acquisition Corp -cl A Com Cl A | 2.3 | $5.5M | 563k | 9.77 | |
| Avadel Pharmaceuticals Sponsored Adr | 2.0 | $4.7M | 580k | 8.08 | |
| Syndax Pharmaceuticals (SNDX) | 1.9 | $4.5M | 206k | 21.89 | |
| Cyteir Therapeutics | 1.9 | $4.5M | 392k | 11.37 | |
| Bellus Health Com New | 1.8 | $4.2M | 525k | 8.05 | |
| Kura Oncology (KURA) | 1.7 | $4.1M | 292k | 14.00 | |
| Apricus Biosciences | 1.7 | $4.1M | 2.5M | 1.63 | |
| Athira Pharma (ATHA) | 1.7 | $4.0M | 310k | 13.03 | |
| Health Sciences Acquisitions Ord Shs | 1.7 | $4.0M | 393k | 10.08 | |
| Verastem | 1.6 | $3.8M | 1.9M | 2.05 | |
| Fulcrum Therapeutics (FULC) | 1.5 | $3.5M | 200k | 17.69 | |
| Iovance Biotherapeutics (IOVA) | 1.4 | $3.4M | 180k | 19.09 | |
| Alpine Immune Sciences (ALPN) | 1.3 | $3.2M | 230k | 13.85 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 1.3 | $3.0M | 243k | 12.24 | |
| Mirati Therapeutics | 1.2 | $2.9M | 20k | 146.70 | |
| Aldeyra Therapeutics (ALDX) | 0.8 | $2.0M | 500k | 4.00 | |
| Sierra Oncology Com New | 0.6 | $1.5M | 69k | 21.74 | |
| Aclaris Therapeutics (ACRS) | 0.6 | $1.4M | 98k | 14.54 | |
| Gossamer Bio (GOSS) | 0.6 | $1.4M | 120k | 11.31 | |
| Molecular Templates | 0.5 | $1.3M | 323k | 3.92 | |
| Galera Therapeutics (GRTX) | 0.5 | $1.2M | 263k | 4.59 | |
| Jounce Therapeutics | 0.4 | $1.1M | 128k | 8.35 | |
| Nuvation Warrants *w Exp 07/07/202 (NUVB) | 0.1 | $172k | 91k | 1.89 |
